Company Active LTD

Company profile

Xstrahl Limited

Radiation Research & eBt Therapy Equipment Company | Xstrahl

A leading radiation equipment company, Xstrahl designs and manufactures X-ray systems for use in radiation therapy and research environments. Learn more.

CRN
03105256
Founded
1995
Age
30

Overview

Legal name
XSTRAHL LIMITED
Region
West Midlands
Registered address
UNIT 2
MAYBROOK ROAD
WALSALL
WEST MIDLANDS
UNITED KINGDOM
WS8 7DG
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

6 events
06 Oct
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

22 Sep
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

08 Oct
2024

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzQzODc3OTE2NWFkaXF6a2N4

Published 08 Oct 2024 08:32

22 Sep
1995

Incorporated

Inception

Company registered at Companies House

Public funding

6 awards
First funded
2014
Funded years
2014, 2016, 2020, 2024
Age at first award
18 years

Projects

2024 Collaborative R&D Lead participant

FLASH Pre Clinical Dosimetry

1 Jan 2024 to 30 Jun 2024

Awarded
£10,795
Total cost £17,991

Recent radiation studies with ultra-high dose rates, UHDR, (\>40 Gy/s), known as FLASH radiotherapy (RT), have demonstrated a remarkable reduction in normal tissue toxicity (known as the "FLASH effect") with respect to conventional dose-rate radiotherapy (few Gy/min) while maintaining similar tumour response. This could represent a step-change in cancer t...

2020 Study Lead participant

A novel high-dose rate and high throughput x-ray irradiation technology for replacement of isotopic sources in radiobiology applications.

1 Feb 2020 to 31 Oct 2021

Awarded
£335,700
Total cost £479,571

The bulk of radiation studies are carried out by isotopic sources (Co60/Cs137), due to their ability to provide a high irradiation rate. However, such sources have become subject to tightening restrictions due to increasing fears surrounding the health and safety (dangerous to human health), security (stolen samples have the potential to be used as weapon...

2016 Collaborative R&D

Development of a pre-clinical dosimetry service with multipurpose small animal phantom for radiotherapy studies

1 Mar 2016 to 28 Feb 2019

Awarded
£37,216
Total cost £62,027

The implementation of standardized and traceable dosimetry procedures for preclinical radiation studies supported by an innovative multipurpose small animal phantom funded by Innovate UK to the tune of £450,000 aims to significantly improve the quality and impact of radiobiological studies whilst reducing the number of animals sacrificed. The collaboratio...

2014 Collaborative R&D Lead participant

Clinical Asssesment of Compact Gamma Camera: An advancement in cancer diagnosis

1 Nov 2014 to 31 Jan 2016

Awarded
£508,849
Total cost £874,462

The project aims to address the recognised need for greater accuracy in Sentinel Lymph Node Biopsy (SLNB), the standard procedure for evaluating & diagnosing a range of cancers - notably breast cancer & melanoma, through the development & clinical testing of a unique Compact Gamma Camera (CGC). The device will not only improve SLNB accuracy (to ~99.5%) bu...

2014 GRD Development of Prototype Lead participant

The Compact Gamma Camera (CGC) – An advancement in imaging for cancer diagnosis

1 May 2014 to 30 Apr 2015

Awarded
£250,000
Total cost £746,829

Sentinel Lymph Node Biopsy (SLNB) is a minimally invasive surgical technique which determines the likelihood of cancer spreading from a primary tumour & becoming metastatic throughout the lymphatic system. It is the most common procedure for evaluating & diagnosing breast cancer & melanoma which have both experienced a significant rise in incidence global...

2014 GRD Development of Prototype Lead participant

The NGX System – an Advancement in Precision Medicine for Radiotherapy of the Skin

1 Jan 2014 to 31 Mar 2015

Awarded
£249,969
Total cost £679,078

Since Roentgen’s discovery in 1895, X-rays have been used for diagnosis and treatment. Today, approximately 50% of all the cancer patients undergo some form of radiotherapy. The use of radiotherapy is particularly effective for the treatment of skin cancer, the prevalence of which has increased dramatically over the past decade, with one in every three ca...

Product types

Collaborative R&D GRD Development of Prototype Study